The therapeutic development of antisense oligonucleotides (ASOs) has expanded its reach to encompass diseases like Huntington's, Alzheimer's, and Parkinson's.

Given their ability to pinpoint disease pathogenesis's root cause, ASOs are a hopeful avenue for addressing stubborn illnesses and genetic disorders.

Explore our resource library to learn more about oligonucleotides and their potential, from synthesis techniques to innovative applications.

Poster Presentations:

Application of Mitra Microsampling for the Quantitative Bioanalysis of ASOs 
Development of a Surrogate Cerebrospinal Fluid Matrix for Quantitative Analysis of ASOs by Hybridization LC-MS 
Development of an Oligonucleotide Drug Immunogenicity Assay 

eBook:

Bioanalytical Development for the Analysis of ASOs

Special Issue of The Altascientist:

Antisense Oligonucleotides (with two case studies!)

Research Articles:

A Novel Hybridization LC-MS/MS Methodology for Quantification of siRNA in Plasma, CSF, and Tissue Samples

Accurate Quantification of ASOs in Mouse Serum Using Microsampling LC-MS/MS

Altasciences has been recognized as a 2023 CRO Leadership Award Champion in the Capabilities category, as voted by you in ISR’s annual CRO Quality Benchmarking survey.

At Altasciences, we specialize in diverse immunomodulators, including proteins, oligonucleotides, biologics, bispecific antibodies, and gene therapy.

Our evaluations count on essential biomarkers, like cytokines, complement factors, immune cell subtyping, and functional measurements.

Rely on us for:

• precise drug quantitation and biomarker assessment;
• state-of-the-art bioanalytical platforms to monitor multiple aspects of     immunomodulation in various species;
• bioanalytical teams with relevant experience handling pathogens and working with infectious samples for your vaccine development programs; and
• labs equipped with containment Level 2 (CL2) areas for handling pathogens within the Risk Group 2.

VIEW FACT SHEET

Need more guidance? Send us a message.

You may also be interested in the below resources: 

• eBook: Key Biomarkers of Immunomodulation: Complement Factors and Cytokines
• Webinar: Development of a Cell-Based Assay for Dual Purposes
• Webpage: Bioanalytical Platforms

Altasciences has been recognized as a 2023 CRO Leadership Award Champion in the Capabilities category, as voted by you in ISR’s annual CRO Quality Benchmarking survey.

Listen to the Latest Audiobook Releases of The Altascientist

Delve deeper into the critical processes behind early phase drug development with audio versions of The Altascientist, written by our experts with you in mind:

Issue 31 — The Advantages of Conducting Early Phase Clinical Research in Canada Find out you can accelerate your early phase clinical research by six to nine weeks in comparison with trials conducted in the U.S. Listen to the audiobook >>>	Issue 32 — A Changing Paradigm for Non-rodent Species in Nonclinical Safety Studies Discover the increasing body of evidence that supports the use of miniature swine as a viable option for your small and large molecule studies. Listen to the audiobook >>>​​​
Issue 33 — CNS Drug Development: Integrated Solutions Lessen Complexity Hear about the complexities of CNS drug development programs and how an integrated CRO/CDMO can help move your molecule seamlessly from one phase to the next. Listen to the audiobook >>>	In Case You Missed It:  Issue 30 — The Evolution and Advancement of LCMS in Drug Development Learn how the latest LC-MS advancements ensure accurate and precise data delivery in your drug development program. Listen to the audiobook >>>